June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
One year retrospective analysis of ocriplasmin for the treatment of symptomatic vitreomacular traction
Author Affiliations & Notes
  • filofteia Tacea
    Ophthalmology, Aintree University Hospital , Liverpool, United Kingdom, United Kingdom
  • Leonidas Makris
    Ophthalmology, Aintree University Hospital , Liverpool, United Kingdom, United Kingdom
  • Ahmed Kamal
    Ophthalmology, Aintree University Hospital , Liverpool, United Kingdom, United Kingdom
  • Footnotes
    Commercial Relationships   filofteia Tacea, None; Leonidas Makris, None; Ahmed Kamal, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 224. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      filofteia Tacea, Leonidas Makris, Ahmed Kamal; One year retrospective analysis of ocriplasmin for the treatment of symptomatic vitreomacular traction. Invest. Ophthalmol. Vis. Sci. 2017;58(8):224.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy and safety of a single intravitreal injection of ocriplasmin in symptomatic patients with vitreomacular traction (VMT).

Methods : Retrospective analysis of all patients with symptomatic metamorphopsia, micro-scotomas and deterioration of vision secondary to VMT, confirmed with Spectral Domain Optical Coherence Tomography (SD-OCT). Patients received a single injection of ocriplasmin (JETREA®). LogMAR visual acuity, measurement of intraocular pressure (IOP) and SD-OCT were recorded at their first follow-up at 1 month, at 3 months and at the final follow-up visit at 12 months.

Results : Thirty-three patients (10 males and 23 females) and a total of 35 eyes were included in our study. Fifteen out of 35 eyes (42.8%) experienced complete release of the VMT. One out of three eyes with a small full thickness macular hole (33.3%) closed post-injection. One eye developed partial thickness macular hole with spontaneous closure at 3 months, after a successful VMT release. Mean visual acuity improved by 6.2 logMAR letters and central macular thickness decreased by an average of 55μm in this group of 15 eyes that achieved VMT release. Twelve out of these 15 eyes (80%) also experienced improvement of symptoms. Despite a successful VMT release in three eyes, there was no improvement in their visual symptoms. The safety review showed that visual symptoms such as vitreous floaters and photopsia were common early after ocriplasmin injection, but rapidly resolved afterwards.

Conclusions : Intravitreal ocriplasmin in carefully selected patients is a promising and safe treatment option for VMT in symptomatic patients and it could represent a viable alternative to pars plana vitrectomy.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×